loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Onvansertib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Onvansertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: 1034616-18-6, Nms-1286937, Nms-p937, Onvansertib free base, Onvansertib [usan], Nms-p937 (nms1286937)
    Molecular Formula
    C24H27F3N8O3
    Molecular Weight
    532.5  g/mol
    InChI Key
    QHLVBNKYJGBCQJ-UHFFFAOYSA-N
    FDA UNII
    67RM91WDHQ
    Onvansertib is an orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide
    2.1.2 InChI
    InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)
    2.1.3 InChI Key
    QHLVBNKYJGBCQJ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CN1CCN(CC1)C2=CC(=C(C=C2)OC(F)(F)F)NC3=NC=C4CCC5=C(C4=N3)N(N=C5C(=O)N)CCO
    2.2 Other Identifiers
    2.2.1 UNII
    67RM91WDHQ
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(2-hydroxyethyl)-8-(5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino)-4,5-dihydropyrazolo(4,3-h)quinazoline-3-carboxamide

    2.3.2 Depositor-Supplied Synonyms

    1. 1034616-18-6

    2. Nms-1286937

    3. Nms-p937

    4. Onvansertib Free Base

    5. Onvansertib [usan]

    6. Nms-p937 (nms1286937)

    7. Pcm-075

    8. Nms1286937

    9. 67rm91wdhq

    10. Chembl1738758

    11. Onvansertib (usan)

    12. 1-(2-hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide

    13. 1-(2-hydroxyethyl)-8-[[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl]amino]-4,5-dihydropyrimido[5,4-g]indazole-3-carboxamide

    14. 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide

    15. Nms 1286937

    16. 1h-pyrazolo(4,3-h)quinazoline-3-carboxamide, 4,5-dihydro-1-(2-hydroxyethyl)-8-((5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl)amino)-

    17. 1-(2-hydroxyethyl)-8-(5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino)-4,5-dihydropyrazolo(4,3-h)quinazoline-3-carboxamide

    18. 1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, 4,5-dihydro-1-(2-hydroxyethyl)-8-[[5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl]amino]-;1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, 4,5-dihydro-1-(2-hydroxyethyl)-8-[[5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl]amino]-

    19. Unii-67rm91wdhq

    20. 1-(2-hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1h-pyrazolo(4,3-h)quinazoline-3-carboxamide

    21. Onvansertib [inn]

    22. Onvansertib [who-dd]

    23. Gtpl7918

    24. Nms P937

    25. Schembl1228019

    26. Dtxsid701025917

    27. Hms3653g04

    28. Hms3673e21

    29. Bcp28066

    30. Ex-a1590

    31. Bdbm50343559

    32. Nsc781344

    33. Nsc800806

    34. S7255

    35. Who 11172

    36. Zinc43196885

    37. Ccg-269924

    38. Cs-3146

    39. Db15110

    40. Nsc-781344

    41. Nsc-800806

    42. Sb16941

    43. Ncgc00386361-03

    44. Ac-36303

    45. Hy-15828

    46. Nms-1286937,nms-p937

    47. B4094

    48. Sw219402-1

    49. A13045

    50. D11458

    51. A896452

    52. Polo-like Kinase 1 Inhibitor Nms-1286937

    53. Q27087959

    54. 1-(2-hydroxy-ethyl)-8-[5-(4-methyl-piperazin-1-yl)-2-trifluoromethoxy-phenylamino]-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide

    55. 1-(2-hydroxyethyl)-8-(5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenylamino)-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide

    56. 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl]amino}-1h,4h,5h-pyrazolo[4,3-h]quinazoline-3-carboxamide

    2.4 Create Date
    2010-12-20
    3 Chemical and Physical Properties
    Molecular Weight 532.5 g/mol
    Molecular Formula C24H27F3N8O3
    XLogP32
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count7
    Exact Mass532.21582124 g/mol
    Monoisotopic Mass532.21582124 g/mol
    Topological Polar Surface Area135 Ų
    Heavy Atom Count38
    Formal Charge0
    Complexity817
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

    Post Enquiry
    POST ENQUIRY